Opening book details…
Can I read Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial on EtoBox?
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial by Zhengbo Song; Yuping Li; Shiqing Chen; Shenpeng Ying; Shuguang Xu; Jianjin Huang; Dan Wu; Dongqing Lv; Ting Bei; Shuxun Liu; Xiaoping Huang; Congying Xie; Xiaoyu Wu; Jianfei Fu; Feng Hua; Wenxian Wang; Chunwei Xu; Chan Gao; Shangli Cai; Shun Lu; Yiping Zhang is a Medicine article available to read on EtoBox.
What is Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial about?
## Abstract ## Background There is currently a lack of effective treatments for non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and potential resistance mechanism to, pyrotinib, a pan-HER inhibitor, in advanced NSCLC carrying HER2 mutations. ## Methods In this multicenter, single-arm, phase II trial, stage IIIB-IV NSCLC patients harboring HER2 mutations, as determined using next-generation sequencing, were enrolled and treated with pyrotinib at a dose of 400 mg/day. The primary endpoint was 6-month progression-free survival (PFS) rate, and secondary endpoints were objective response rate (ORR), PFS, overall survival (OS), disease control rate (DCR), and safety. The impact of different HER2 mutation types on sensitivity to pyrotinib and the potential of utilizing mutational profile derived from circulating tumor DNA (ctDNA) to predict disease progression were also explored. ## Results Seventy-eight patients were enrolled for efficacy and safety analysis. The 6-month PFS rate was 49.5% (95% confidence interval [CI], 39.2–60.8). Pyrotinib produced an ORR of 19.2% (95% CI, 11.2–30.0), with median PFS of 5.6 months (95% CI, 2
Who reads Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Zhengbo Song; Yuping Li; Shiqing Chen; Shenpeng Ying; Shuguang Xu; Jianjin Huang; Dan Wu; Dongqing Lv; Ting Bei; Shuxun Liu; Xiaoping Huang; Congying Xie; Xiaoyu Wu; Jianfei Fu; Feng Hua; Wenxian Wang; Chunwei Xu; Chan Gao; Shangli Cai; Shun Lu; Yiping Zhang
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)